Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Executive Summary
Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.
You may also be interested in...
‘Real World’ Opioid Abuse Data On OxyContin Again Under Review At US FDA
Resubmission comes more than four years after Purdue pulled an sNDA seeking to demonstrate ‘real-world’ abuse prevention.
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Morphine sulfate extended-release product’s approval with only one of three routes of abuse raises questions about how effectively US FDA’s policies are encouraging development of abuse-deterrent opioid formulations.
If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market
Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.